Yamanaka Factors: The Short Read

The Backup Copy

A baby is young. A child born to parents in their forties starts at zero. Pristine tissues, clock wound all the way back, even though it was built entirely from the cells of two adults whose bodies had been racking up decades of wear. Somewhere in the handoff from one generation to the next, the aging clock gets reset to nothing.

This is not a figure of speech. In 2021, researchers tracking the biological age of mouse embryos found that age doesn’t simply start low and climb. It first drops. Early in development, biological age falls to the lowest point it will ever hit. The reproductive cells that carry life forward grow old like everything else. But in the embryo, they get scrubbed clean. Nature already knows how to make an old cell young. It does it on schedule, once per generation, in every species that has ever lived. The entire field of cellular reprogramming is the attempt to trigger that same reset on purpose, not inside an embryo, but in the living tissue of a full-grown adult.

That ambition rests on a contrarian idea about what aging is. The intuitive view is that the body wears out the way a machine does. Joints erode. Parts rust. Damage piles up until the whole thing fails. The competing account says the cell’s DNA stays remarkably intact as we age. What degrades is the layer of control sitting on top of it: which genes are switched on, which stay silent. The contrarian claim is that aging is largely the corruption of those settings. Not the hard drive physically failing, but the files getting scrambled. And scrambled data, unlike a gear worn down to nothing, can in principle be restored. This is sometimes called the information theory of aging. Aging is not damage to be repaired, but information to be recovered.

Why believe the original is still recoverable? Because in 2006, someone recovered it. The proof came out of Shinya Yamanaka’s lab in Kyoto. Yamanaka and his colleague Kazutoshi Takahashi started with two dozen candidate switches known to be active in embryonic cells, then took them out one at a time. The answer was startlingly small: just four. Force those four proteins into an ordinary adult cell, and the cell winds back into something that closely resembles a cell from a days-old embryo. A fully specialized cell, returned to a near-blank slate. The result earned Yamanaka a share of the 2012 Nobel Prize. The four proteins are now called the Yamanaka factors. Their initials spell OSKM: Oct4, Sox2, Klf4, and c-Myc.

There’s a reason this hasn’t already become medicine. Reprogramming, carried to completion, doesn’t merely make a cell younger. It makes it forget. Push it all the way back and a liver cell stops being a liver cell. A cell wiped clean and set dividing without restraint sits dangerously close to the definition of a tumor. And one of the four factors, c-Myc, is a notorious cancer-promoting gene. So the whole enterprise reduces to a question of degree and control. Can you wind a cell’s clock partway back while stopping short of erasing what kind of cell it is? Can you hit undo without holding the button down too long?

The Goldilocks Window

Both age and identity are stored in the same place: the layer of chemical settings sitting on top of the DNA. Methylation tags. The way DNA is wound around protein spools. The cell writes, erases, and rewrites these every hour. A defensive maintenance crew constantly patrols the genome and stamps the original pattern right back, which is why a liver cell stays a liver cell for fifty years instead of slowly forgetting the job. That same defense is what makes reprogramming so hard, and the same erasability is what makes reversal possible at all.

For years, the field was stuck on a single problem. The same act that winds a cell’s clock backward also makes it forget what it is. If age and identity are welded together, then rejuvenation is hostage to amnesia. You can’t buy the first without paying for it with the second.

The breakthrough came in 2019. Researchers mapped a full reprogramming course in detail, tracking the epigenetic clock (a methylation-pattern age-reader that scores how old a cell looks chemically) as cells crept toward the stem-cell state. What they found is that biological age doesn’t fall in step with the loss of identity. It falls first. The clock starts ticking backward within the first few days and drops steadily, while the genes that stamp a cell as a fibroblast keep right on running well past that point. A critical window opens, provisionally somewhere between day three and day thirteen. Slip in, and slip out before roughly day thirteen, and you collect the youth without paying the toll.

Charting the window on a graph is one thing. Actually pulling it off is another. That fell to Wolf Reik’s group at the Babraham Institute outside Cambridge, England. The result made headlines in April 2022. They took skin cells from donors averaging around fifty years old and switched on the four factors. Instead of letting the process run to completion, they cut the factors off at day thirteen. The cells reverted cleanly to fibroblasts, no half-finished limbo. But they weren’t the fibroblasts they used to be. By the epigenetic clock, they read about thirty years younger than when they started.

And they behaved younger. Fibroblasts are the body’s repair and scaffolding crew. They make collagen, the protein that gives skin its structure, and they migrate into wounds to knit them closed. Both abilities fade with age. The treated cells made more collagen, the way young fibroblasts do. When the researchers scratched a clean gap across a sheet of them, the cells crawled in to fill it faster, with the brisk closing-in of young tissue. They’d recovered not just the molecular look of youth but its function. No cells had ever been wound back so many years and still kept their identity and their job. The two effects that had appeared welded together had been pried apart.

This is the Goldilocks problem. Too little reprogramming does nothing. Too much tips the cell into cancer or amnesia. The safe middle is narrow, and the window’s location and width shift with the cell type, the tissue, the individual, that person’s age, and how the factors are delivered. Finding the window, then holding a living body inside it, is the bottleneck the entire industry is built around.

The Four-Billion-Dollar Race

The money chasing the Goldilocks problem is coming from a strange place. Not from the big pharmaceutical companies, but from the personal fortunes of tech billionaires. The four most ambitious reprogramming companies have together pulled in well over $4 billion. Much of it came from people who made their money in software, online retail, and crypto. Not biology.

The largest single bet, and the largest startup launch in the history of biotech, is Altos Labs. It came out of stealth in January 2022 with $3 billion and the backing of Jeff Bezos and Yuri Milner’s science foundation. Robert Nelsen, co-founder of the storied biotech venture firm ARCH Venture Partners, put the deal together. Hal Barron, until then the head of research at the drug giant GlaxoSmithKline, was hired as CEO. Rick Klausner, a former director of the U.S. National Cancer Institute, became chief scientist. Altos is all-in on the classic Yamanaka factors. The defining choice: Altos has no lead drug. It has, on purpose, no single disease it’s racing toward. The mission is to understand the basic biology of rejuvenation first, before committing to any one product. In an industry built around picking a target and driving it to market, this is close to heresy. Altos finally moved in 2025. It hired Joan Mannick, a leading clinical-trials veteran from the mTOR-inhibitor field, as Chief Medical Officer in August and began its first early human safety testing the same month.

Retro Biosciences, seeded in 2021 with $180 million from OpenAI’s Sam Altman, runs on a very different philosophy. It runs three programs at once, and only one of them is actually Yamanaka-style reprogramming. The other two go after distinct aspects of aging: autophagy (the cell’s built-in garbage disposal) and the old observation that something in the blood of young animals seems to rejuvenate the tissues of old ones. The telling detail is which of the three reached patients first. It wasn’t reprogramming. Retro’s furthest-advanced clinical asset is RTR242, a small molecule that restores lysosomal function. It entered Phase 1 in Adelaide in 2025, aimed at Alzheimer’s. By late 2025, Retro was raising roughly $1 billion in fresh financing, pushing its valuation toward $1.8 billion.

NewLimit, founded in 2022 by Coinbase CEO Brian Armstrong and investor Blake Byers, goes straight at the central danger. Importantly, NewLimit isn’t using the original Yamanaka factors. Its bet is that you find safer alternatives using machine learning. The company’s “lab in a loop” platform searches for entirely different transcription-factor combinations that rejuvenate while staying clear of the dangerous stem-cell state. After raising $130 million from Kleiner Perkins, NewLimit took another $45 million from Eli Lilly in late 2025. The Lilly money is the more interesting signal. Big pharma had stayed almost entirely on the sidelines of reprogramming until now.

If Altos is maximal patience, Life Biosciences is the opposite: get to a patient first. Built around the work of the Harvard biologist David Sinclair, Life uses the three-factor OSK gene therapy. This is the Yamanaka trio that drops the cancer-linked fourth factor. It rides into cells on the harmless AAV virus and is switched on with the doxycycline antibiotic. The target is the eye, and the choice is shrewd. The eye is small, enclosed, immune-privileged, and reachable through a routine outpatient injection. You have two of them, so a trial can treat one and leave the other as a built-in control. Life’s lead candidate, ER-100, goes after diseases of the optic nerve. On January 28, 2026, the FDA cleared Life’s application to test ER-100 in people. The study enrolls 18 patients. It’s the first cellular-reprogramming rejuvenation therapy ever allowed into a human trial.

Calico, launched in 2013 by Google with the former Genentech CEO Arthur Levinson at the head, is the older, broader effort. It isn’t a reprogramming company at all. It’s a basic-research institute aimed at the fundamental biology of aging in every form, studying among other things the naked mole-rat, a rodent that barely seems to age. More than a decade and billions of dollars in, Calico has produced deep science but no breakthrough therapy.

For all the money, the field has produced exactly one therapy cleared to enter a human body. ER-100, in the eye. That’s not an accident. It’s a strategy. No regulator yet recognizes aging as a disease, so every company has to enter the clinic through the narrow door of a specific, approvable condition. Behind ER-100, the next round of programs is lining up. In the liver, the dual Altos–NewLimit attack is the most plausible second win. In the immune system, Retro’s autologous stem-cell route, if it works, would be the deepest rejuvenation of all. In the brain, YouthBio Therapeutics is working through Alzheimer’s. Underneath all of these sits the longer-shot small-molecule pill that Sinclair’s lab hinted at in 2023.

What Winning Would Mean

There’s no credible path here to a 150-year human life. The hardware damage sets a ceiling reprogramming was never built to break. Rewinding a cell’s settings cannot rebuild dead neurons, un-mutate corrupted DNA, or dissolve the stiffened scaffolding between cells. People who promise otherwise are selling something.

The right number to track isn’t maximum lifespan. It’s the healthspan-lifespan gap: the years people live but don’t live well. The global average of that gap is about 9.6 years, by one 2024 analysis, and over 12 years in the United States. That’s a decade of failing eyes, weakening hearts, fading minds. The physician James Fries named the goal in 1980: compression of morbidity. Squeeze illness into a brief window just before the end, so that a long healthy life is followed by a short decline rather than a drawn-out one. That’s not philosophy. It’s what every program running today is, in practical terms, aiming at.

Read the field through that lens and the picture becomes simple. Life Biosciences is testing whether old eyes can see again. Altos and NewLimit are testing whether old livers can metabolize like young ones. Retro is testing whether failing waste-handling in the brain can be restarted, and whether a patient’s own blood cells can be regrown from a younger state. YouthBio is testing whether brief reprogramming pulses can slow Alzheimer’s. None of those programs adds a single year to the maximum human lifespan. Together, if even a few of them work, they take large bites out of the decade of decline.

A child born today will likely live in a world where the failing eyes, weakening hearts, and fading minds of late life are no longer accepted as the price of getting older. They will be treated, one organ at a time, with medicines that wind their cells back. Where aging itself is partly a condition rather than only a fate. Where the line between growing old and growing ill has, for the first time in human history, visibly moved.

Reprogramming wouldn’t let people live forever. It might let them stay whole almost until they die.

And even if it never adds one year to the outer limit of human life, closing that decade-wide gap would rank among the largest gains in human welfare ever achieved. The first hard evidence comes in the next two or three years, from a few dozen patients in a glaucoma clinic, asked to read a chart they couldn’t read before.